this type of stent is very well tolerated in humans. The same group24 showed that phosphorylcholine coated stents had low rates of subacute stent thrombosis (0%) and restenosis (12%), even when used in the setting of primary PCI for acute myocardial infarction. Phosphorylcholine-coated stents have also been examined in the setting of PCI of small coronary vessels. In a retrospective series of 90 patients undergoing stenting of vessels 2.0 to 2.8 mm in diameter, Beaudry et al25 reported a MACE rate of 20%. Similar results have been obtained after deploying these stents in vessels 2.0 mm in diameter. 26 Unfortunately, the lack of routine follow-up angiography is the major limitation of these 5 studies, and although well tolerated, it is unclear if phosphorylcholine-coated stents inhibit neointimal hyperplasia to a significant degree (Table 2).